Prospective Liver Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01539993
Recruitment Status : Completed
First Posted : February 28, 2012
Last Update Posted : May 28, 2014
Information provided by (Responsible Party):
Hyun Kevin Kim, Emory University

Brief Summary:
This study is designed for patients diagnosed with Liver cancer to collect information about the relationship between types of liver cancer, methods of treatment and outcomes over time.

Condition or disease
Liver Cancer

Study Type : Observational
Actual Enrollment : 400 participants
Time Perspective: Prospective
Official Title: Prospective Analysis of Liver Cancer Treatment and Interventions
Study Start Date : November 2008
Primary Completion Date : January 2014
Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Cancer
U.S. FDA Resources


Primary Outcome Measures :
  1. Assess efficacy of percutaneous and transarterial treatments for liver cancer. [ Time Frame: 1 month ]
    QOL questionnaire will be collected during follow up visit.

Secondary Outcome Measures :
  1. long term follow up [ Time Frame: 3 months, 6 months 1year ]
    Patients will be administered QOL during 3 months, 6 months and 1 year follow up.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients 18 yrs and older with a diagnosis of Hepatocellular carcinoma and elegible for percutaneous liver treatments

Inclusion Criteria:

  • Patients diagnosed with Hepatocellular carcinoma and referred for percutaneous liver treatment.

Exclusion Criteria:

  • Severe liver disfunction
  • Active uncontrolled infection
  • Significant underlying medical of physical illness

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01539993

United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
Principal Investigator: Kevin S Kim, MD Emory University

Responsible Party: Hyun Kevin Kim, MD FSIR, Director of Interventional Radiology and Image-Guided Medicine., Emory University Identifier: NCT01539993     History of Changes
Other Study ID Numbers: IRB00014768
First Posted: February 28, 2012    Key Record Dates
Last Update Posted: May 28, 2014
Last Verified: May 2014

Keywords provided by Hyun Kevin Kim, Emory University:
Hepatocellular carcinoma
Liver metastases
Percutaneous treatments

Additional relevant MeSH terms:
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases